USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING A SPASTIC MUSCLE
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
1 . A method for treating a spastic muscle, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of a botulinum toxin to thereby treat the spastic muscle, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin obtained by fermenting Clostridium botulinum.
2 . The method of claim 1 wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
3 . The method of claim 1 wherein the botulinum toxin is botulinum toxin type A.
4 . The method of claim 1 wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
7 . The method of claim 1 wherein the neurotoxic component is administered by intramuscular injection.
8 . The method of claim 1 wherein the spastic muscle is a facial muscle.
9 . The method of claim 1 wherein the spastic muscle is a jaw muscle.
10 . The method of claim 1 wherein the spastic muscle is a throat muscle.
11 . The method of claim 1 wherein the spastic muscle is a vocal chord muscle.
12 . The method of claim 1 wherein the spastic muscle is a leg muscle.
13 . The method of claim 12 wherein the spastic muscle is a thigh muscle.
14 . The method of claim 1 wherein the spastic muscle is a hand muscle.
15 . The method of claim 1 wherein the spastic muscle is a wrist muscle.
16 . The method of claim 1 wherein the spastic muscle is a forearm muscle.
17 . The method of claim 1 wherein the spastic muscle is a smooth muscle.
18 . The method of claim 17 wherein the smooth muscle is a sphincter.
19 . The method of claim 18 wherein the smooth muscle sphincter is a gastrointestinal system smooth muscle sphincter.
20 . The method of claim 18 wherein the smooth muscle sphincter is a urinary smooth muscle sphincter.
21 . The method of claim 18 wherein the smooth muscle sphincter is a rectal sphincter.
22 . A method for treating a spastic muscle, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of only a botulinum toxin type A, to thereby treat the spastic muscle, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin obtained by fermenting Clostridium botulinum.
23 . The method of claim 22 wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
24 . The method of claim 22 wherein the neurotoxic component is administered by intramuscular injection.
25 . The method of claim 22 wherein the spastic muscle is a facial muscle.
26 . The method of claim 22 wherein the spastic muscle is a jaw muscle.
27 . The method of claim 22 wherein the spastic muscle is a throat muscle.
28 . The method of claim 22 wherein the spastic muscle is a vocal chord muscle.
29 . The method of claim 22 wherein the spastic muscle is a leg muscle.
30 . The method of claim 29 wherein the spastic muscle is a thigh muscle.
31 . The method of claim 22 wherein the spastic muscle is a hand muscle.
32 . The method of claim 22 wherein the spastic muscle is a wrist muscle.
33 . The method of claim 22 wherein the spastic muscle is a forearm muscle.
34 . The method of claim 22 wherein the spastic muscle is a smooth muscle.
35 . The method of claim 34 wherein the smooth muscle is a sphincter.
36 . The method of claim 35 wherein the smooth muscle sphincter is a gastrointestinal system smooth muscle sphincter.
37 . The method of claim 35 wherein the smooth muscle sphincter is a urinary smooth muscle sphincter.
38 . The method of claim 35 wherein the smooth muscle sphincter is a rectal sphincter.
39 . A method for treating a spastic muscle, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component from a single botulinum toxin type selected from the group consisting of the botulinum toxin types A, B, C, D, E, F and G to thereby treat the spastic muscle, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin obtained by fermenting a Clostridium botulinum bacterium.
40 . The method of claim 39 wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
41 . The method of claim 39 , wherein the neurotoxic component is administered by intramuscular injection.
42 . The method of claim 39 wherein the spastic muscle is a facial muscle.
43 . The method of claim 39 wherein the spastic muscle is a jaw muscle.
44 . The method of claim 39 wherein the spastic muscle is a throat muscle.
45 . The method of claim 39 wherein the spastic muscle is a vocal chord muscle.
46 . The method of claim 39 wherein the spastic muscle is a leg muscle.
47 . The method of claim 46 wherein the spastic muscle is a thigh muscle.
48 . The method of claim 39 wherein the spastic muscle is a hand muscle.
49 . The method of claim 39 wherein the spastic muscle is a wrist muscle.
50 . The method of claim 39 wherein the spastic muscle is a forearm muscle.
51 . The method of claim 39 wherein the spastic muscle is a smooth muscle.
52 . The method of claim 51 wherein the smooth muscle is a sphincter.
53 . The method of claim 52 wherein the smooth muscle sphincter is a gastrointestinal system smooth muscle sphincter.
54 . The method of claim 52 wherein the smooth muscle sphincter is a urinary smooth muscle sphincter.
55 . The method of claim 52 wherein the smooth muscle sphincter is a rectal sphincter.
56 . The method of claim 39 wherein the botulinum toxin is a botulinum toxin type A.